Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CX3C chemokine receptor 1 (CX3CR1), also known as the fractalkine receptor or GPR13, is a transmembrane protein belonging to the G protein-coupled receptor (GPCR) family. Its primary endogenous ligand is fractalkine (CX3CL1), which exists in both membrane-bound and soluble forms. The interaction between CX3CL1 and CX3CR1 mediates cell adhesion, migration, and retention of leukocytes. It plays a key role in immune response, inflammation, cell adhesion, and chemotaxis and is associated with various diseases including neurodegenerative, inflammatory, cardiovascular diseases and cancer.
Modulates survival, migration, proliferation of target cells via intracellular signaling cascades after ligand binding.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CX3C Chemokine Receptor 1 (CX3CR1).